0.76 USD
+0 (+0.07%)
0.76 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 83% to BRNS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.61. This target is 638.16% above the current price.
BRNS was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BRNS.
In the previous month the buy percentage consensus was at a similar level.
BRNS was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-13 | Barclays | Maintains | Overweight |
| 2024-06-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
BARINTHUS BIOTHERAPEUTICS PL / BRNS FAQ
What is the average price target for BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?
8 analysts have analysed BRNS and the average price target is 5.61 USD. This implies a price increase of 638.16% is expected in the next year compared to the current price of 0.76.
What is the consensus rating for BRNS stock?
The consensus rating for BARINTHUS BIOTHERAPEUTICS PL (BRNS) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.